Evaluation of a new commercial dilute prothrombin time in the diagnosis of Lupus Anticoagulants

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 404-411

  Devreese, Katrien M J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT; PROTHROMBIN; THROMBOPLASTIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CLOTTING TEST; BLOOD SAMPLING; DIAGNOSTIC PROCEDURE; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; PRIORITY JOURNAL; PROTHROMBIN TIME; SCREENING; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOSIS;

HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 55549146799     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.005     Document Type: Article

References (35)

1. Arnout J. Antiphopholipid syndrome: diagnostic aspects of lupus anticoagulants. Throm Haemost 86 (2001) 83-91
2. Greaves M., Cohen H., Machin S.J., Mackie I., and on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109 (2000) 704-715
3. de Groot P.G., Lutters B., Derksen R.H.W.M., Lisman T., Meijers J.C.M., and Rosendaal F.R. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 3 (2005) 1993-1997
4. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827-1832
5. 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphopholipid syndrome. Blood 102 (2003) 2717-2723
6. 2 -glycoprotein I- dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004) 3598-3602
7. Zoghlami-Rintelen C., Vormittag R., Sailor T., Lehr S., Quehenberger P., Rumpold H., et al. The presence of IgG antibodies against beta-2-glycoprotein I predicts the risk of thrombosis in patients with lupus anticoagulant. J Thromb Haemost 3 (2005) 1160-1165
8. 2 -glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005) 1540-1545
9. 2-glycoprotein I and prothrombine, and risk of thrombosis. J Thromb Haemost 3 (2005) 1231-1238
10. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
11. Miyakis S., Lockshin M.D., Atsumi D., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
12. Exner T., Triplett D.A., Taberner D., and Machin S.J. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 65 (1991) 320-322
13. Brandt J.T., Triplett D.A., Alving B., and Scharrer I. Criteria for diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74 (1995) 1185-1190
14. Gardiner C., Mackie I.J., Malia R.G., Jones D.W., Winter M., Leeming D., et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 111 (2000) 1230-1235
15. Derksen R.H., and de Groot P.G. Tests for lupus anticoagulant revisited. Thromb Res 114 (2004) 521-526
16. Arnout J., Vanrusselt M., Huybrechts E., and Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 87 (1994) 94-99
17. Arnout J. ISTH Scientific Standardisation Subcommitte Lupus Anticoagulants/Phospholipid dependent antibodies. International Society of Thrombosis and Haemostasis, Boston (July 2000)
18. Devreese K. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 119 (2007) 369-376
19. Triplett D.A. Assays for detection of antiphospholipid antibodies. Thromb Haemost 70 (1993) 787-793
20. Triplett D.A., Barna L.K., and Unger G.A. A hexagonal (II) phase phopholipid neutralization assay for lupus anticoagulant identification. Lupus 3 (1994) 281-287
21. Jacobson E.M., Barna-Cler L., Taylor J.M., Triplett D.A., and Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 104 (2001) 275-282
22. Jennings I., Kitchen S., Woods T.A., Preston F.E., and Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 77 (1997) 934-937
23. Arnout J., Meijer P., and Vermylen J. Lupus anticoagulant testing in Europe: An analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta-2-glycoprotein I. Thromb Haemost 81 6 (1999) 929-934
24. Robertson B., and Greaves M. Antiphospholipid syndrome: An evolving story. Blood Reviews 20 (2006) 201-212
25. Lackner K.J., Peetz D., and von Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome-coming to grips with evidence and Thomas Bayes?. Thromb Haemost 95 (2006) 917-919
26. Lawrie A.S., Mackie I.J., Purdy S., and Machin S.J. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 81 (1999) 758-762
27. Chantarangkul V., Tripodi A., Arbini A., and Mannucci P.M. Silica clotting time (SCT) as a screening and confirmatory test for lupus anticoagulants. Thromb Res 67 4 (1992) 355-365
28. Schjetlein R., and Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am J Clin Pathol 103 1 (1995) 108-111
29. Dragoni F., Minotti C., Palumbo G., Faillace F., Redi R., Bongarzoni V., et al. As compared to kaolin clotting time, silica clotting time is a specific and sensitive automated method for detecting lupus anticoagulant. Thromb Res 45 (2001) 45-51
30. Tripodi A., Chantarangkul V., Clerici M., and Mannucci P.M. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Thromb Haemost 88 (2002) 583-586
31. Wisloff F., Jacobsen E.M., and Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 108 (2003) 263-271
32. Grypiotis P., Ruffatti A., Peno V., Tonella M., Biasiolo A., Zamboni D., et al. Use of a new silica clotting time for diagnosis lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome. J Clin Lab Anal 20 (2006) 15-18
33. Devreese K.M.J. Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants. Thromb Res 120 (2007) 427-438
34. Passam F., and Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 36 2 (2004) 129-138
35. Liestol S., Jacobsen E.M., and Wisloff F. Dilute prothrombin time-based lupus ratio test Integrated LA testing with recombinant tissue thromboplastin. Thromb Res 105 (2002) 177-182